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Lytic infectionThe Epstein–Barr virus (EBV) lytic program elicits ATM-dependent DNA damage response, resulting in
phosphorylation of p53 at N-terminus, which prevents interaction with MDM2. Nevertheless, p53-
downstream signaling is blocked. We found here that during the lytic infection p53 was actively degraded
in a proteasome-dependent manner even with a reduced level of MDM2. BZLF1 protein enhanced the
ubiquitination of p53 in SaOS-2 cells. The degradation of p53 was observed even in the presence of Nutlin-3,
an inhibitor of p53-MDM2 interaction, and also in mouse embryo ﬁbroblasts lacking mdm2 gene, indicating
that the BZLF1 protein-induced degradation of p53 was independent of MDM2. Furthermore, Nutlin-3
increased the level of p53 in the latent phase of EBV infection but not in the lytic phase. Although p53 level is
regulated by MDM2 in the latent phase, it might be mediated by the BZLF1 protein-associated E3 ubiquitin
ligase in the lytic phase for efﬁcient viral propagation.
© 2009 Elsevier Inc. All rights reserved.Introduction
The Epstein–Barr virus (EBV), a human herpesvirus harboring a
170 kbp dsDNA genome, can choose between two alternative life
cycles (Tsurumi, 2001). Primary EBV infection targets resting B
lymphocytes, inducing their continuous proliferation. In B lympho-
blastoid cell lines, the viral genome is maintained as circular plasmids
forming nucleosomal structures with histones and there is no
production of virus particles, this being called latent infection.
When production of virus is induced, the circular genome becomes
a ready template for ampliﬁcation, generating thousands of copies per
cell during lytic replication. The EBV lytic program is initiated by the
expression of the viral immediate-early (IE) BZLF1 protein (Country-
man and Miller, 1985; Rooney et al., 1989), which is a b-zip
transcriptional factor which binds to AP-1-like sequences present in
the promoters of early lytic genes (Farrell et al., 1989; Urier et al.,
1989). Viral lytic replication occurs in discrete sites in nuclei, called
replication compartments in which seven viral replication proteins,
including BZLF1 protein which also acts oriLyt binding protein, are
assembled (Takagi, Takada, and Sairenji, 1991).e Society for the Promotion of
ll rights reserved.Induction of the EBV lytic program elicits a cellular DNA damage
response, with activation of the ataxia-telangiectasia mutated (ATM)
signal transduction pathway (Kudoh et al., 2005). The DNA damage
sensor, MRN complex (Mre11, Rad50, and Nbs1), and phosphorylated
ATM are recruited and retained in viral replication compartments,
recognizing newly synthesized viral DNAs as abnormal DNA struc-
tures. ATM DNA damage signaling activates Chk1/Chk2, leading to
phosphorylation and stabilization of p53 (Kudoh et al., 2005). In
general, ATM-initiated checkpoint signaling induces a p53-dependent
response, featuring p21WAF1/CIP1-mediated inactivation of Cdk2/
Cyclin E (Dulic et al., 1994; el-Deiry et al., 1993; Gu, Turck, and
Morgan, 1993), leading to increase in levels of p53, p21WAF1/CIP1,
MDM2 and hypophosphorylated Rb. However, the level of the
p21WAF1/CIP1 CDK inhibitor remains unchanged and low throughout
lytic infection, while the amounts of cyclin E/A and the hyperphos-
phorylated form of Rb increase (Kudoh et al., 2004; Kudoh et al., 2003;
Kudoh et al., 2005). Thus, despite activation of the ATM checkpoint
signaling, p53-downstream signaling is blocked, with rather high
S-phase CDK activity associated with progression of lytic infection.
The tumor suppressor p53 plays an important role in maintaining
genomic integrity (Sherr, 2004; Vogelstein, Lane, and Levine, 2000). In
unstressed normal cells, p53 usually exists in latent form and at low
levels due to rapid degradation through the ubiquitin-dependent
proteasomepathway (Zhang andXiong, 2001).MDM2 is a key regulator
of p53 turnover by binding to p53 and promote its ubiquitination by
Fig. 2. Induction of EBV lytic replication promotes proteasome-dependent degradation
of p53. (A) Turnover of p53 is enhanced after induction of EBV lytic replication. Tet-
BZLF1/B95-8 cells were cultured with (circle) or without (square) doxycycline for 48 h
and treated with or without 20 μMMG132 for 3 h before harvesting. Cells were cultured
in the presence of cycloheximide (CHX) for the indicated hours before harvesting. The
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phosphorylated at Ser15 by ATM, preventing the interaction with
MDM2, subsequently leading to escape from degradation by protea-
some. The p53 protein level is elevated, resulting in an increase in p53-
dependent transcription of its target genes, subsequently leading to cell
cycle arrest or apoptosis (Bourdon et al., 2003; Oren, 2003).
To hijack the host cell systemwith evading host security responses
and lead to an advantageous environment for viral replication, a
number of viruses have amodulator(s) of p53 function. The E6 protein
of the high-risk human papillomaviruses and the cellular ubiquitin–
protein ligase E6AP form a complex which causes the ubiquitination
and degradation of p53 (Band et al., 1993; Scheffner et al., 1990). The
adenovirus E1B 55-kDa protein interacts directlywith p53 and inhibits
its acetylation (Martin and Berk, 1998). E4 Orf6 binds to both p53 and
E1B 55 k and the trimeric complex directs the ubiquitination of p53
and thus targets it for degradation (Querido et al., 2001).
In case of EBV, the BZLF1 immediate-early protein has been
reported to be an important modulator of p53 function. Zhang et al.
have shown that the BZLF1 protein directly binds to p53 and inhibits
its ability to activate a reporter construct containing p53 binding
motifs (Zhang, Gutsch, and Kenney, 1994). However, in comparison
with the effects of the smaller DNA viruses, much less is known
regarding the mechanism by which the protein inhibits transcrip-
tional functions of p53. In this study, we found that the BZLF1 protein
enhanced the ubiquitin-mediated degradation of p53. Since the
degradation of p53 was observed even in the presence of Nutlin-3,
an inhibitor of MDM2–p53 interaction, and also in mouse embryo
ﬁbroblasts lacking mdm2 gene, the degradation of p53 was indepen-
dent of MDM2 function. While p53 level is regulated by MDM2 in the
latent phase, it is strongly suggested that p53 level might be
downregulated by the BZLF1 protein-associated E3 ubiquitin ligase
in the lytic phase. The regulation of p53 by the BZLF1 protein might
serve to enhance the efﬁciency of lytic EBV replication.
Results
Downregulation of expression levels of p53 and its target-gene product,
MDM2, in the late stages of the EBV lytic infection
We have previously demonstrated that induction of EBV lytic
replication elicits ATM-dependent DNA damage signal response withFig.1. Expression proﬁles of p53, MDM2, and TBP after induction of EBV lytic replication.
Tet-BZLF1/B95-8 cells, and B95-8 cells were cultured in the presence of 2 mg/ml of
doxycycline, and chemical inducers (Sodium butylate (5 mM), TPA (0.2 μg/ml) and
A23187 (1 μM)), respectively, and then harvested at the indicated times. Cell lysates
were prepared, and applied for immunoblot analysis with speciﬁc antibodies as
indicated. IR, Tet-BZLF1/B95-8 cells were exposed to 10 Gy of γ-irradiation, harvested
2 h post-treatment, and processed similarly.
levels of p53 and GAPDH were assessed by immunoblotting. Decay curves of p53 were
generated from the band quantiﬁcation after normalization against GAPDH. The data
shownwere obtained from at least three independent experiments and are mean±S.E.
values. (B) Proteasome-dependent degradation of p53 during EBV latent and lytic
infection. Tet-BZLF1/B95-8 cells were cultured with or without of Dox for 43 h and then
treated for 5 h with the proteasome inhibitor MG132 or DMSO as a control. Expression
of p53 was analyzed by immunoblotting using anti-p53 antibodies with short and long
exposure. (Ub)n-p53 indicates the ubiquitinated form of p53. (C) p53 ubiquitination in
lytic infection. Ubiquitinated proteins were precipitated with anti-multi Ub antibodies
fromwhole cell extracts of lytic replication-induced Tet-BZLF1/B95-8 cells treated with
MG132 and probed with the anti-p53 antibody. IP, immunoprecipitation.phosphorylation of ATM, NBS1, Chk2, and p53 but that p53 down-
stream signaling is blocked (Kudoh et al., 2005). It is known that
phosphorylation of p53 at Ser15 in response to DNA damage usually
correlates with both accumulation of total p53 and the ability of p53 to
transactivate downstream target genes. Lytic replication was induced
in Tet-BZLF1/B95-8 cells with doxycycline (Dox) and cells were
harvested at the indicated times. As shown in Fig.1 (left panel), despite
increase in levels of p53 phosphorylated at Ser15, levels of p53
reduced gradually with the progression of the lytic replication. Also,
levels of the p53-transcriptional gene target MDM2, which is a
negative regulator of p53, substantially declined as the lytic replica-
tion progressed. These results suggest that p53 is downregulated after
induction of lytic infection even with a reduced level of MDM2. In
contrast, levels of TBP throughout the lytic replication proved constant
Fig. 3. p53 is associated with BZLF1 protein in the lytic phase of EBV replication. Nuclear
extracts were prepared from lytic replication-induced Tet-BZLF1/B95-8 cells with
doxycycline (24 h.p.i.) in the presence of DMSO or MG132 (20 μM, 5 h). Immunopre-
cipitationwas performed with monoclonal anti-p53 or normal mouse IgG2a antibodies,
followed by Western blotting using anti-BZLF1 protein, and anti-p53 antibodies. IP,
immunoprecipitation.
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the level of TBP in some cell lines (Mauser et al., 2002). Progression of
the lytic infection was monitored by the expression of the EBV single
stranded DNA binding BALF2 early protein. Similar results were also
obtained under the conditions that the lytic infection was induced by
addition of chemical compounds in B95-8 cells (Fig. 1; right panel). In
Akata cell line, an EBV-positive Burkitts' cell line, however, we could
not observe any detectable level of p53 due to frame-shift mutation of
p53 gene. Since many Burkitts' cell lines harbors mutations of p53Fig. 4. BZLF1 protein enhances ubiquitination of p53 in SaOS-2 cells. (A) Expression of BZLF1
p53 and BZLF1 expression plasmids as indicated, re-seeded 8 h post-transfection and the
transfection. Cell lysateswere prepared and applied for immunoblot analysis with the indicat
2KO cells transfected with p53 and BZLF1 expression plasmids as indicated, were cultured
immunoblot analysis with the indicated antibodies. (C) Turnover of p53 is stimulated in the p
plasmids and re-seeded 8 h post-transfection, followed by addition of cycloheximide (CHX) t
lysateswere subjected to immunoblot analysis for p53 andGAPDH (control). (D) BZLF1 promo
of FLAG-p53, BZLF1 protein and HA-Ub expression vectors, exposed to ionizing radiation 21
transfection. Cell lysates were subjected to immunoprecipitation with anti-FLAG antibody, afrequently, it should be noted that such cell lines are not suitable for
the analyses.
Proteasome-dependent degradation of p53 after induction of the lytic
infection even with a reduced level of MDM2
Based on the observation that steady-state levels of p53 protein are
gradually decreased following the progression of EBV lytic replication
(Fig. 1), we monitored turnover of p53 in both latent and lytic phase.
The half-life of p53 was shortened after induction of lytic infection
(Fig. 2A). To further examine whether the decrease of p53 protein
level is caused by proteasome-dependent degradation during the lytic
infection, lytic replication-induced Tet-BZLF1/B95-8 cells were trea-
ted with or without MG132, 26S proteasome inhibitor. Although
induction of lytic replication reduced the level of p53, the addition of
MG132 increased the level of p53, including some modiﬁed forms
detected as slowly migrating bands (Fig. 2B). We validated that a
ladder of bands corresponded to polyubiquitinated p53 by immuno-
precipitation (IP) assay with anti-Multi ubiquitin antibody (Fig. 2C).
Therefore, the level of p53 was regulated by ubiquitin-mediated
proteasomal degradation not only before but also after induction of
lytic replication, even with a reduced level of MDM2. Usually when
p53 is phosphorylated at Ser15 by ATM in response to DNA damege,
the phosphorylation prevents the interaction with MDM2, leading to
decrease in ubiquitination levels of p53. However, p53 was ubiquiti-
nated to similar level to that before induction.protein accelerates proteasomal degradation of p53. SaOS-2 cells were transfected with
n treated with DMSO or MG132 for the indicated times before harvesting 24 h post-
ed antibodies. (B) Treatment ofMG132 also restores p53 level inMDM2 null background.
in the presence of DMSO or MG132 for 4 h. Cell lysates were prepared and applied for
resence of BZLF1 protein. SaOS-2 cells were transfected with p53 and BZLF1 expression
o the cell cultures. Cells were cultured for the indicated hours before harvesting. The cell
tes polyubiquitination of p53. SaOS-2 cells were transfectedwith different combinations
h post-transfection and treated with 20 μMMG132 for 2 h before harvesting 24 h post-
pplied to SDS-PAGE, and then immunoblotted with anti-HA antibody.
Fig. 5. Repression of p53-mediated transactivation by BZLF1 protein requires the
physically interaction between p53 and BZLF1 protein. (A) Repression of p53-mediated
transactivation by the BZLF1 protein requires physical interaction between p53 and the
BZLF1 protein. SaOS-2 cells were transfected withWWP-Luc reporter plasmids together
with pCMV-Rluc, pGFP and various combinations of expression plasmids as indicated.
Luciferase activity was measured 24 h post-transfection. Values are averages from three
independent transfections (±S.E.) after normalization against the internal control
(Renilla activity). Lysates of the luciferase samples were analyzed by Western blotting
with indicated antibodies. (B) Human cytomegalovirus IE promoter was not affected by
the BZLF1 protein. SaOS-2 cells were transfected with pCMV-Luc reporter plasmids
together with BZLF1 protein expression plasmids as indicated ratio. Luciferase activity
was measured 24 h post-transfection and relative values were calculated with that in
the absence of BZLF1 protein expression plasmid taken as 100%. Values are averages of
three independent transfections (±S.E.) Lysates of luciferase samples were analyzed by
Westren blotting with anti-BZLF1 and anti-GAPDH antibodies.
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especially in the presence of a proteasome inhibitor MG132
The results described above suggest that p53 signaling pathway is
blocked through the degradation of p53. EBV BZLF1 immediate-early
protein is a good candidate for downregulating p53, since it has been
shown that BZLF1 protein interacts with p53 (Kudoh et al., 2005;
Zhang, Gutsch, and Kenney, 1994). We previously reported that
immunoprecipitation with anti-BZLF1 speciﬁc antibody against
lysates from lytic replication-induced B95-8 cells co-precipitated
both BZLF1 and p53 proteins (Kudoh et al., 2005). Inversely,
immunoprecipitation using anti-p53 speciﬁc antibody was performed
with lysates from lytic infection-induced Tet-BZLF1/B95-8 cells in the
presence and absence of a proteasome inhibitor MG132 (Fig. 3).
Appreciable association of p53 with BZLF1 protein was conﬁrmed in
the presence of MG132, but hardly in its absence under the condition.
This observation suggests the possibility that p53 is a substrate for the
BZLF1 protein-associated E3 ubiquitin ligase, since the association of
ubiquitin ligase with its targets usually results in rapid degradation of
the substrates.
Ubiquitination and proteasome-dependent degradation of p53 in the
presence of the BZLF1 protein in SaOS-2 cells
To address whether the decrease of p53 protein level is caused by
proteasome-dependent degradation also in SaOS-2 cells, cells were
co-transfected with p53 and BZLF1 expression plasmids and treated
with MG132 (Fig. 4A). Treatment with MG132 resulted in restoration
of the expression level of p53 in the cells where both p53 and BZLF1
protein were overexpressed, similar to the level of p53 when the cells
were transfected with p53 expression vector alone (Fig. 4A). We also
conﬁrmed that the proteasomal inhibition by MG132 abolished the
BZLF1 protein-mediated degradation of p53 in an MDM2 null
background using p53- and mdm2-genes double knock out mouse
embryo ﬁbroblasts, 2KO cells (Montes de Oca Luna, Wagner, and
Lozano, 1995) (Fig. 4B). Next, the co-transfection experiments were
performed in the presence of cycloheximide. Consistently, the
cycloheximide-chase assay revealed that turnover of p53 was
accelerated in the presence of BZLF1 protein compared with the
absence of BZLF1 protein (Fig. 4C).
We found the enhancement of p53-ubiquitination by BZLF1
protein in the presence of MG132 (Fig. 4D), implying that the BZLF1
protein causes proteasome-dependent degradation of p53 by
ubiquitination.
Direct interaction between the BZLF1 protein and p53 is required for the
repression of p53-mediated transactivation and p53 degradation
It has been previously reported that p53-mediated transactivation
is repressed by expression of the BZLF1 protein in reporter gene assay
(Mauser et al., 2002; Zhang, Gutsch, and Kenney, 1994). In order to
examine the effect of the BZLF1 protein on p53-responsive transcrip-
tion in detail, theWWP-Luc reporter plasmid, containing an authentic
p21 promoter, was co-transfected with expression plasmids for p53
and BZLF1 protein into p53-null SaOS-2 cells. As shown in Fig. 5A, the
p53-mediated transactivation was strongly repressed by the BZLF1
protein. In contrast, with the BZLF1 d200-227 mutant lacking p53
interaction domain (Zhang, Gutsch, and Kenney,1994), this repression
was abolished (Fig. 5A), suggesting that the physical interaction
between BZLF1 protein and p53 was required for repression of p53-
mediated transactivation. Western blot analysis of the lysate used in
the luciferase reporter assay revealed that the levels of p53 protein
were reduced with expression of the wild-type BZLF1 protein but not
with the d200-227 mutant. With GFP monitoring of transfection
efﬁciency, TBP and GAPDH expression proved constant in the presence
and absence of BZLF1 protein, although it has been proposed that anindirect mechanism exists involving suppression of TBP expression by
the BZLF1 protein (Mauser et al., 2002). Therefore, it appears that
direct association of BZLF1 protein to p53 is required for repression of
p53-speciﬁc transcription and elevated p53 degradation. It should be
noted that p53 expression was not regulated by the BZLF1 protein,
since the p53 protein was exogenously expressed from a human
cytomegalovirus (HCMV) IE promoter that was not affected by the
BZLF1 protein (Fig. 5B).
MDM2 is not required for the degradation of p53 by the BZLF1 protein
In unstressed cells, MDM2 regulates p53 quantitatively and
promote its ubiquitination by acting as an E3 ubiquitin ligase (Zhang
and Xiong, 2001). To determine whether MDM2 is required for the
BZLF1 protein-mediated suppression of p53, 2KO (p53−/−/mdm2−/−)
cells were used. As shown in Fig. 6A, the BZLF1 protein repressed the
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reporter plasmid containing p53-binding sites and allowing p53-
speciﬁc transcription to bemonitored. BZLF1 protein reduced the level
of p53 protein in 2KO cells. On the other hand, TBP and GAPDH
expression proved constant in the presence and absence of the BZLF1
protein. Furthermore, repression of p53-mediated transactivation by
the BZLF1 protein correlated with the reduction of p53 was observed
also in SaOS-2 cells expressing very low level of MDM2 (Capoulade et
al., 2001; Chen et al., 2005b), even with Nutlin-3 that can disrupt thep53-MDM2 interaction (Vassilev et al., 2004) (Fig. 6B). Collectively,
the results clearly demonstrated that MDM2 could not be involved in
the BZLF1 protein-mediated p53 degradation.
Finally, to examine whether the degradation of p53 requires
MDM2 in the context of the lytic infection, Tet-BZLF1/B95-8 cells were
treatedwith Nutlin-3 in the presence or absence of doxycycline.While
treatment with Nutlin-3 increased the levels of p53 just in the latent
phase of infection, the compound did not change the levels of p53 in
the lytic phase (Fig. 6C). Taken together, although MDM2 controls the
amount of p53 protein in the latent infection, after induction of the
lytic infection another E3 ligase might be involved in ubiquitin-
mediated proteasomal degradation of p53.
Discussion
Inhibition of p53-mediated transactivation is essential for regulat-
ing the cellular environment advantageous for viral replication in lytic
infection. This is in general agreement with a lot of reports on
herpesvirus family. The molecular mechanism of inactivating p53 is
controversial. For instance, in the cells infected with HCMV, pIE-86
interferes with the acetylation of p53 and of histones by directly
binding to the histone acetyltransferase p300/CBP and then down-
regulates p53-driven transcription (Hsu et al., 2004). Other reports on
herpes simplex virus type 1 (HSV-1) (Wilcock and Lane, 1991) and
HCMV (Fortunato and Spector, 1998) showed that the sequestration of
p53 in viral replication sites as called replication compartments or
centers might play a role in maintaining p53 in an inactive state. In
this study, we demonstrated that expression of the EBV BZLF1 protein
induced ubiquitin-mediated proteasomal degradation of p53 inde-
pendent of MDM2 and resulted in reduction of the p53 protein levels,
explaining the downregulation of the transcriptional function of p53
during the EBV lytic infection.
In the latent phase of EBV infection, p53 levels are regulated by
MDM2 as demonstrated by Nutlin-3 treatment (Fig. 6C). One
important question that arises is whether MDM2, which is clearly a
major regulator of p53 stability, is required for the ubiquitin-mediated
degradation of p53 by BZLF1 protein during the EBV lytic infection.We
found that level of MDM2 decreased and p53 was phosphorylated at
least at Ser15 in the late stages of lytic infection (Fig. 1). Under this
condition, the interaction between p53 and MDM2 is weakened
because of the phosphorylation of p53 N-terminus (Shieh et al., 1997).
Moreover, p53 degradation was observed even in 2KO cells lacking
MDM2 in the presence of the BZLF1 protein (Fig. 6A) and also in the
Nutlin-3 treated lytic infection-induced cells (Fig. 6B). Therefore, p53
are also ubiquitinated and degraded during the lytic infection, but
being independent of MDM2. These ﬁndings provide us the newFig. 6. MDM2 is not required for the BZLF1 protein-mediated downregulation of p53.
(A) Repression of p53-mediated transactivation by the BZLF1 protein is independent of
MDM2. 2KO (p53−/−, MDM2−/−) cells were transfected with PG13-Luc or MG15-Luc
reporter plasmids together with pCMV-Rluc and various combinations of expression
plasmids. Luciferase activity was measured 24 h post-transfection. Values are averages
from three independent transfections (±S.E.) after normalization against the internal
control (Renilla activity). Lysates of the luciferase samples were analyzed by Western
blottingwith indicated antibodies. (B) p53-speciﬁc transcription activity is repressed by
expression of BZLF1 protein in a dose-dependent manner. SaOS-2 cells were transfected
with PG13-Luc or MG15-Luc reporter plasmids containing a tandem array of wild-type
or mutated p53-binding sites together with pCMV-Rluc as an internal control, and p53
and BZLF1 protein expression plasmids as indicated. Cells were treated with DMSO or
Nutlin-3 (10 μM) for 8 h before harvesting. Luciferase activities were measured 24 h
post-transfection. Values are averages from three independent transfections (±S.E.)
after normalization against the internal control (Renilla activity). Lysates from the
luciferase assays were applied for immunoblot analysis with anti-p53, anti-BZLF1
protein, anti-HDM2, and anti-GAPDH antibodies. (C) p53 is downregulated indepen-
dent of MDM2 in the lytic infection of EBV. Tet-BZLF1/B95-8 cells were cultured in the
presence (+Dox) or absence (−Dox) of doxycycline. Nutlin-3 or DMSO as a control was
added to the cultures at 42 h post-induction, and cells were harvested 48 h post-
induction. Expression levels of p53 were analyzed by immunoblotting with anti-p53
antibodies.
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phosphorylated p53 via the BZLF1 protein, instead of MDM2, to block
the p53 downstream signaling. The identiﬁcation of several new p53-
E3 ligases, namely Pirh2 (Leng et al., 2003), COP1 (Dornan et al.,
2004), TOPORS (Rajendra et al., 2004) and ARF-BP1 (Chen et al.,
2005a), adds more complexity to the p53 ubiquitination pathway,
suggesting that p53 abundance is tightly regulated by both MDM2-
dependent and -independent mechanisms. It is yet uncertain exactly
how those proteins are speciﬁcally regulated and under what
situations they may be differentially activated. The effect of BZLF1
protein on p53 degradation might reﬂect the upregulation of these
molecules. However, several observations do not favor this model,
although direct evidence during EBV lytic infection has been lacking.
First, similar toMDM2, Pirh2 is a p53 responsive gene and participates
in a similar autoregulatory negative feedback loop (Leng et al., 2003).
Second, as shown in Fig. 1, p53 target genes such as mdm2 were
repressed during EBV lytic replication. Third, DNA damage triggers the
autodegradation of COP1 through ATM-dependent phosphorylation to
permit p53 stabilization (Dornan et al., 2006). Lastly, EBV lytic
replication elicits ATM-dependent DNA damage response (Kudoh et
al., 2005). Therefore, it might be reasonable to predict that these E3
ligases are downregulated during EBV lytic infection. Because there
is no published work regarding regulation of TOPORS and ARF-BP1,
it is difﬁcult to examine if BZLF1 protein could contribute to their
expression or not.
Ubiquitination is important for the regulation of cellular processes,
including signal transduction, development, apoptosis, cell cycle
progression, and immune response (Hershko and Ciechanover, 1998;
Liu, 2004; Pickart, 2001). In the ubiquitin-mediated proteolytic
pathway, there are two distinct steps; (i) the covalent attachment of
multiple ubiquitin molecules to the substrate, and (ii) the degradation
of the polyubiquitinated protein by the 26S proteasome complex
(Hershko and Ciechanover, 1998). The ubiquitination of substrate
requires a cascade of enzymatic reactions involving an E1 activating
enzyme, an E2 conjugating enzyme, and ﬁnally an E3 ligase enzyme
that covalently attaches ubiquitin to lysine residue of target protein
(Scheffner, Nuber, and Huibregtse, 1995). The E3 ligase is generally
thought to be a group of multisubunit complexes, which are mainly
consist of the substrate-speciﬁc adaptor protein, scaffold protein, and
RING ﬁnger-containing protein that interacts with E2 ligase (Bashir et
al., 2004; Kamura et al., 2004; Maxwell et al., 1999; Pintard, Willems,
and Peter, 2004; Wertz et al., 2004; Zheng et al., 2002). This supports
the possibility that ubiquitination of p53 by BZLF1 protein requires for
additional factors, since BZLF1 protein does not possess the RING
ﬁnger domain. Therefore, it is likely that BZLF1 protein rather acts as
an adaptor such as F-box proteins and SOCS-box proteins. Further
studies are required to identify a component of BZLF1 protein-
associated E3 ligase complex involved in the inhibition of p53-
downstream signaling during EBV lytic infection.
However, we cannot rule out the possibility that othermechanisms
are also involved in the inhibition of the p53-downstream signaling by
the BZLF1 protein. Mauser et al. previously showed that BZLF1 protein
substantially reduced the level of cellular TBP in both normal human
ﬁbroblasts and A549 cells and the inhibitory effects of the BZLF1
protein on p53 transcriptional function could be partially rescued by
overexpression of TBP (Mauser et al., 2002). Although suppression of
TBP expression is one of possible explanation for this observation, we
could not observe any suppression of TBP expression in the
transfection system in SaOS-2 cells, 2KO cells (Figs. 5A and 6A). TBP
expression is stimulated with high PKC and/or MAPK activity (Garber,
Vilalta, and Johnson, 1994; Zhong, Zhang, and Johnson, 2004). The
activation of PKC and/or MAPK plays an important role in transition
from latent to lytic EBV infection (Gao et al., 2001; Gao, Wang, and
Sairenji, 2004). Indeed, the reduction of TBP abundance was not
observed also in the lytic replication-induced B95-8 cells and Tet-
BZLF1/B95-8 cells (Fig. 1). Since most viral promoters contain TATAbox and the binding of TBP to these promoters greatly contributes to
the viral gene expressions, it is difﬁcult to be receptive to this
explanation. On the other hands, Zhang et al. found that p53 levels
were actually increased in primary human ﬁbloblasts, IMR-90 cells
where the BZLF1 expression vector was transfected (Zhang, Gutsch,
and Kenney, 1994). Also, Cayrol and Flemington reported that BZLF1
protein induced accumulation of p53 and a G1 arrest through
activation of p21WAF-1/CIP-1 in HeLa cells (Cayrol and Flemington,
1996). We conﬁrmed this observation in HeLa cells conditionally
expressing the BZLF1 protein (data not shown). In the case that BZLF1
protein is transiently overexpressed in D98/HE-R-1 cells (fusion
between HeLa and EBV-positive P3HR1 cells), expression of p53
appears to be increased (Zhang, Gutsch, and Kenney, 1994). Although
a cell-type-speciﬁcity will be a possible explanation for the apparent
discrepancy, the expression balance between p53 and BZLF1 protein
might play a key role in the fate of p53 levels in EBV-positive cells. In
the late stages of infection, degradation of p53 might dominate over
enhancement of p53 expression since expression level of BZLF1
protein gradually increased as shown in this study. Thus, it is likely
that ubiquitin-mediated degradation of p53 by BZLF1 protein is a
major mechanism of regulating p53 function during the EBV lytic
infection.
The present study indicated the existence of distinct mechanisms
of p53 quantitative regulation in the latent and lytic phases of EBV
infection. While the level of p53 was mainly controlled by MDM2-
dependent ubiquitination in latent phase, after induction of lytic
replication, MDM2 hardly interacts with p53 due to N-terminal
phosphorylation of p53 (Shieh et al., 1997) resulted from the ATM-
Chk2 DNA damage-signaling activation by EBV lytic program (Kudoh
et al., 2005). On the basis of our ﬁndings with the BZLF1 protein, we
propose a model for ubiquitination of p53 by the BZLF1 protein-
associated E3 ligases, and this model may help explain how EBV
prevents the cells from arresting in G1-phase or/and apoptosis in
response to the activation of ATM-signal transduction pathway, and
maintains the high S-phase CDK activity that is essential for the
expression of viral genes and lytic viral replication (Kudoh et al.,
2004). The identiﬁcation of the BZLF1 protein-associated E3 ligases is
now in progress.
Materials and methods
Cells and reagents
p53-null human osteosarcoma SaOS-2 cells, and 2KO cells, derived
from mouse embryo ﬁbroblasts lacking the p53 and mdm2 genes
(Montes de Oca Luna, Wagner, and Lozano, 1995), were grown in
DMEM supplemented with 10% fetal calf serum (FCS). 2KO cells were
kindly provided by Dr. G. Lozano (M.D. Anderson Cancer Center). EBV-
positive marmoset B lymphocytes B95-8 cells were cultured in RPMI
medium supplemented with 10% FCS. Tet-BZLF1/B95-8 cells (Kudoh
et al., 2003) were maintained in RPMI medium supplemented with
1 μg of puromycin/ml, 250 μg of hygromycin B/ml, and 10%
tetracycline-free FCS. To induce lytic EBV replication, the tetracycline
derivative doxycycline was added to the culture medium at a ﬁnal
concentration of 2 μg/ml. All cells were grown at 37 °C in a 5% CO2
atmosphere. For MG132 (Sigma) and Nutlin-3 (Cayman chemical)
experiments, cells were treated with MG132 (20 μM)/DMSO, and
Nutlin-3 (10 μM)/DMSO for 0.5–5 h, and 6–8 h respectively, before
harvesting.
Anti-p53 (FL-393) rabbit polyclonal antibody, and normal mouse
IgG2a were purchased from Santa Cruz Biotechnology. Anti-Phosho-
p53 (Ser15) rabbit polyclonal antibodies were obtained from Cell
Signaling Technology. Mouse anti-GAPDH (Ambion), mouse anti-
Multi ubiquitin (FK-2) (MBL), rabbit anti-GFP (Invitrogen), rat anti-
HA (3F10) (Roche), monoclonal mouse anti-p53 (Ab-6) (Merck),
mouse anti-MDM2 (Ab-3) (Merck) and mouse anti-FLAG M2 (Sigma)
210 Y. Sato et al. / Virology 388 (2009) 204–211antibodies were also used. Horseradish-peroxidase-conjugated sec-
ondary antibodies were purchased from Zymed Laboratories. Afﬁnity-
puriﬁed anti-BZLF1, anti-BALF2, and anti-BMRF-1 protein antibodies
were prepared as described previously (Daikoku et al., 2005).
Plasmids and transfection
For the expression of FLAG-tagged p53, expression vectors of full-
length wild-type p53 (FLAG-wtp53) was constructed by inserting of
p53-DNA fragment ampliﬁed by PCR into p3×FLAG-CMV-14 expres-
sion vector (Sigma). A BZLF1 mutant (BZLF1 d200-227), lacking a part
of Zip domain was generated by overlapping PCR. The inserted DNA
sequence of each vector was conﬁrmed by direct DNA sequencing. The
mammalian expression vector for human wild-type p53 (pcNXRS)
and the BZLF1 protein expression vector (pcDNA-BZLF1) were kindly
provided by Dr. T. Takahashi (Nagoya University, Japan) and Dr. K.
Kuzushima (Aichi Cancer Center Research Institute, Japan), respec-
tively. Reporter plasmids such as WWP-Luc, PG13-Luc and MG15-Luc
(el-Deiry et al., 1993) were gifts from Dr. B. Vogelstein (The Johns
Hopkins University Medical Institutions). WWP-Luc, PG13-Luc and
MG15-Luc contain authentic p21 promoter, 13 copies of a p53-binding
site, and 15 copies of a subtlymutated p53-binding site, respectively in
the upstream of reporter gene.
Cellswere seeded, cultured to semiconﬂuence and transfectedwith
expression plasmids using lipofection reagent (Lipofectamine™ and
Plus reagent; Invitrogen) according to manufacturer's instructions.
Immunoprecipitation and Western blotting
Cells were lysed in lysis buffer (50 mM Tris–HCl pH 7.6, 120 mM
NaCl, 0.1% NP40, 1 mM EDTA, 100 mM sodium ﬂuoride, 2 mM sodium
vanadate) containing a protease inhibitor cocktail (Sigma), and then
sonicated. The debris was removed by centrifugation and the super-
natants were applied for immunoprecipitation with speciﬁc anti-
bodies. Complexes of antibody and antigen were collected by
centrifugation and washed three times with NET-gel buffer (50 mM
Tris–HCl pH 7.6, 150 mM NaCl, 0.1% NP40, 1 mM EDTA). The
immunoprecipitates were then subjected to SDS-PAGE followed by
immunoblot analyses. For in vivo ubiquitination assays, SaOS-2 cells
transfected with expression plasmids of HA-ubiquitin, FLAG-p53 and
BZLF1 protein by electroporation using MicroPorator MP-100 (Digital
Bio), were exposed to ionizing radiation with 20 Gy 21 h post-
transfection. Cells were treated with MG132 for 2 h before harvesting
24 h post-transfection and then lysed in lysis buffer containing 20 μM
MG132 and a protease inhibitor cocktail (Sigma) under the denaturing
condition described previously (Murata and Shimotohno, 2006).
FLAG-p53 derivatives were precipitated with anti-FLAG antibody
and detected by immunoblot analysis. Preparation of the lysate for
immunoblotting, Western blotting and detection of signals were
performed as described previously (Sato et al., 2006).
Luciferase reporter assay
Cells seeded in 24-well plates were transfected with 0.05 μg of the
luciferase reporter plasmid (WWP-Luc, PG13-Luc or MG15-Luc), with
or without 0.1 μg of pcNXRS and 0.004, 0.02 or 0.1 μg of pcDNA-BZLF1.
Simultaneously, 0.01 μg of pCMV-Rluc vector DNAwas also transfected
as an internal control. The amount of transfected DNA was kept
constant by adding empty vector. Luciferase activity was measured
with a dual luciferase assay kit (Promega) according to the manufac-
turer's instructions, using a luminometer (Berthoid).
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